Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Arteriosclerosis

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    57 result(s) found for: Arteriosclerosis. Displaying page 1 of 3.
    1  2  3  Next»
    EudraCT Number: 2012-001983-31 Sponsor Protocol Number: 1842012 Start Date*: 2012-05-25
    Sponsor Name:Juha Hartikainen
    Full Title:
    Medical condition: Coronary artery by-pass surgery patients
    Disease: Version SOC Term Classification Code Term Level
    14.1 10007541 - Cardiac disorders 10011076 Coronary artery atherosclerosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-005147-42 Sponsor Protocol Number: 78143605 Start Date*: 2009-02-25
    Sponsor Name:Mª Angeles Aguirre Zamorano
    Full Title: Arteriosclerosis y Lupus Eritematoso Sistémico: ¿Pueden las Estatinas detener este proceso?
    Medical condition: Prevención primaria del desarrollo de arteriosclerosis precoz en pacientes con Lupus Eritematoso Sistémico.
    Disease: Version SOC Term Classification Code Term Level
    9 10003210 Arteriosclerosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-000192-14 Sponsor Protocol Number: TMC-CAN-05-02 Start Date*: 2006-12-21
    Sponsor Name:The Medicines Company
    Full Title: A Clinical Trial Comparing Cangrelor To Clopidogrel In Subjects Who Require Percutaneous Coronary Intervention
    Medical condition: Subjects with coronary atherosclerosis who require PCI (with or without stent).
    Disease: Version SOC Term Classification Code Term Level
    8.1 10011093 Coronary atherosclerosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Prematurely Ended) ES (Completed) DE (Completed) IT (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2009-012206-39 Sponsor Protocol Number: ALX-0081-2.1/09 Start Date*: 2009-08-14
    Sponsor Name:Ablynx
    Full Title: A phase II randomized, open label clinical trial in high risk percutaneous coronary intervention (PCI) patients receiving standard antithrombotic treatment plus either ALX-0081 or GPIIb/IIIa inhibi...
    Medical condition: Thrombotic events associated with percutaneous coronary intervention (PCI) in patients with unstable angina or Non ST-Segment Elevation Myocardial Infarction (NSTEMI), or stable angina with at leas...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10011076 Coronary artery atherosclerosis LLT
    9.1 10011078 Coronary artery disease LLT
    9.1 10013210 Disorder coronary artery LLT
    9.1 10063933 Coronary stent thrombosis LLT
    9.1 10065608 Percutaneous coronary intervention LLT
    9.1 10003211 Arteriosclerosis coronary artery LLT
    9.1 10011067 Coronary angiogram abnormal LLT
    9.1 10011093 Coronary atherosclerosis LLT
    9.1 10011099 Coronary disease LLT
    9.1 10051592 Acute coronary syndrome LLT
    9.1 10011076 Coronary artery atherosclerosis LLT
    9.1 10011093 Coronary atherosclerosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) DE (Completed) CZ (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2011-001488-40 Sponsor Protocol Number: CCFMS181/211 Start Date*: 2011-09-01
    Sponsor Name:FONDAZIONE MONZINO CENTRO CARDIOLOGICO
    Full Title: Antiplatelet effect of low doses of aspirin taken every 12 hours in patients undergoing coronary artery bypass graft and / or aortic valve replacement surgery with bioprostheses
    Medical condition: Coronary Atheroclerosis
    Disease: Version SOC Term Classification Code Term Level
    14.1 10007541 - Cardiac disorders 10003211 Arteriosclerosis coronary artery PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-003684-32 Sponsor Protocol Number: ISTANT Start Date*: 2008-06-18
    Sponsor Name:OSPEDALE S. RAFFAELE
    Full Title: Integrilin plus stenting to avoid myocardial necrosis trial. Pilot Study
    Medical condition: patients with diffuse CAD undergoing percutaneous treatment on a native coronary vassel with planned implantation of 33 mm of DES with reference vessel diameter 2.25-4.0 mm.
    Disease: Version SOC Term Classification Code Term Level
    6.1 10011076 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-004533-15 Sponsor Protocol Number: PENTA Start Date*: Information not available in EudraCT
    Sponsor Name:Johannes Gutenberg-Universität Mainz, II. Med. Klinik (ausführende Stelle), Prof. Dr. T. Münzel
    Full Title: Effect of 8 weeks oral Pentaerithrityltetranitrate on endothelial dysfunction in patients with coronary artery disease: A prospective, randomized, double-blind, placebo-controlled, monocentric c...
    Medical condition: Women or men >35 and < 80 years of age with documented, clinically stable coronary artery disease with stable angina pectoris from the heart catheter register, II. Med. Klinik, Johannes Gutenberg-U...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10049194 Stable angina pectoris LLT
    9.1 10011093 Coronary atherosclerosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-006295-17 Sponsor Protocol Number: MedTrace-002 Start Date*: 2022-04-08
    Sponsor Name:MedTrace Pharma
    Full Title: A Phase 3, Multicenter, Open Label Study to Confirm the Diagnostic Potential of Intravenously Administered 15O- H2O to Identify Coronary Artery Disease During Pharmacological Stress and Resting Con...
    Medical condition: Coronary Artery Disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004849 10006896 CAD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2012-000458-72 Sponsor Protocol Number: 260411 Start Date*: 2012-05-25
    Sponsor Name:Juha Hartikainen
    Full Title:
    Medical condition: Coronary artery by-pass surgery patients
    Disease: Version SOC Term Classification Code Term Level
    14.1 10007541 - Cardiac disorders 10011076 Coronary artery atherosclerosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2006-003935-56 Sponsor Protocol Number: TMC-CAN-05-03 Start Date*: 2006-11-24
    Sponsor Name:The Medicines Company
    Full Title: A clinical trial comparing treatment with cangrelor (in combination with usual care) to usual care, in subjects who require percutaneous coronary intervention
    Medical condition: Subjects with coronary atherosclerosis (excluding ST segment-elevation MI [STEMI]) who require PCI (with or without stent).
    Disease: Version SOC Term Classification Code Term Level
    8.1 10011093 Coronary atherosclerosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) ES (Completed) CZ (Prematurely Ended) LT (Completed) SK (Completed) DE (Prematurely Ended) IT (Completed)
    Trial results: View results
    EudraCT Number: 2010-021591-28 Sponsor Protocol Number: TMC-CAN-10-01 Start Date*: 2011-01-05
    Sponsor Name:The Medicines Company
    Full Title: A clinical trial comparing cangrelor to clopidogrel standard of care therapy in subjects who require percutaneous coronary intervention
    Medical condition: Subjects with coronary atheroschlerosis who require PCI
    Disease: Version SOC Term Classification Code Term Level
    15.0 10007541 - Cardiac disorders 10011076 Coronary artery atherosclerosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) CZ (Completed) IT (Completed) DE (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2016-003521-42 Sponsor Protocol Number: ARG-E08 Start Date*: 2017-02-09
    Sponsor Name:Mitsubishi Tanabe Pharma GmbH
    Full Title: SAICoDis – Safety of Argatroban Infusion in Conduction Disturbances. A prospective, open, multicenter safety study to investigate conduction disturbances in patients receiving argatroban therapy.
    Medical condition: Patients without diagnosed HIT II but with a coronary heart disease and with a diagnosed stable or unstable angina are planned for a percutaneous coronary intervention (PCI) according to clinical r...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10007541 - Cardiac disorders 10003211 Arteriosclerosis coronary artery PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2011-004567-80 Sponsor Protocol Number: ILOFLOW1.0 Start Date*: 2012-06-05
    Sponsor Name:Georg Hagmüller Institute for Vascular Research
    Full Title: The intraoperative arterial measurement of the blood flow after Iloproststimulation in diabetics and non-diabetics: Implication for Outcome - prediction and perioperative therapy.
    Medical condition: We think that the blood flow increases during intraarterial injection of iloprost during surgical treatment in distal vessels in patients with arteriosclerosis and diabetes and non diabetes in the ...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-002677-53 Sponsor Protocol Number: CL2-78989-009 Start Date*: 2012-12-19
    Sponsor Name:Institut de Recherches Internationales Servier (I.R.I.S.)
    Full Title: Evaluation of the subcutaneous administration of 30 mg of S 78989 versus placebo and evaluation of the subcutaneous administration of 60 mg of S 78989 versus placebo on the reduction of arterial wa...
    Medical condition: Arterial wall inflammation in patients with marked atherosclerotic plaque inflammation
    Disease: Version SOC Term Classification Code Term Level
    16.0 100000004849 10057703 Coronary atherosclerosis of non-autologous biological bypass graft LLT
    16.0 100000004849 10058152 Coronary atherosclerosis of bypass graft LLT
    16.0 100000004866 10018104 Generalized and unspecified atherosclerosis LLT
    16.0 100000004866 10002892 Aortic atherosclerosis LLT
    16.0 100000004849 10011093 Coronary atherosclerosis LLT
    16.0 100000004866 10003603 Atherosclerosis generalized LLT
    16.0 100000004849 10011095 Coronary atherosclerosis of native coronary artery LLT
    16.0 100000004866 10003605 Atherosclerosis of aorta LLT
    16.0 100000004866 10051615 Atherosclerotic cardiovascular disease LLT
    16.0 100000004849 10011094 Coronary atherosclerosis of autologous biological bypass graft LLT
    16.0 100000004849 10011076 Coronary artery atherosclerosis LLT
    16.0 100000004849 10011097 Coronary atherosclerosis of unspecified vessel LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2006-000171-15 Sponsor Protocol Number: IMT-MRI-Trial-2006 Start Date*: 2007-01-17
    Sponsor Name:University Hospital of Ulm
    Full Title: Randomized, placebo-controlled, double-blinded study evaluating the effects of Pioglitazone on intima-media-thickness (IMT) of the carotid arteries measured by MRI in non-diabetic patients with con...
    Medical condition: Male or female non-diabetic patients at an age between 30 and 79 years (inclusive) with a proven vascular disease defined as arteriosclerosis confirmed by presence of CAD, PAD or carotid plaques.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-001743-31 Sponsor Protocol Number: NL43882.029.13 Start Date*: 2013-08-06
    Sponsor Name:VU University Medical Center
    Full Title: The cardiovascular effects of hyperoxia during and shortly after CABG surgery
    Medical condition: During and after coronary artery bypass graft operation we will investigate the cardiovascular effects of hyperoxia on blood pressure, cardiac function, microcirculation and ischemia/reperfusion.
    Disease: Version SOC Term Classification Code Term Level
    16.0 100000004866 10051615 Atherosclerotic cardiovascular disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-005288-33 Sponsor Protocol Number: EMI111784 Start Date*: 2008-12-18
    Sponsor Name:GlaxoSmithKline Research & Development, LtdD
    Full Title: Methodology Study to develop Sinerem enhanced 3T MR Imaging of Atherosclerotic Plaques within the Carotid Arteries, and to compare Sinerem MRI to contrast enhanced ultrasound
    Medical condition: Atherosclerotic plaque within the carotid artery.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10051615 Atherosclerotic cardiovascular disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-006922-32 Sponsor Protocol Number: HOADO Start Date*: 2009-02-09
    Sponsor Name:RUNMC
    Full Title: Heme oxygenase (HO) activity in humans. Effects of heme arginate (Normosang®) on parameters of HO activity and on adenosine induced vasodilation.
    Medical condition: Normosang treatment will be used to evaluate heme oxygenase induction in healthy subjects. Results will be used for future studies concerning diabetes related cardiovascular disease.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10051615 Atherosclerotic cardiovascular disease LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-006447-40 Sponsor Protocol Number: CSPP100A2366 Start Date*: 2009-02-23
    Sponsor Name:Novartis Farmacéutica
    Full Title: Estudio multicéntrico, aleatorizado, doble ciego, con grupos paralelos y de 104 semanas de duración, para evaluar la eficacia de aliskiren en la progresión de la aterosclerosis en pacientes con enf...
    Medical condition: Progresión de la aterosclerosis en pacientes con enfermedad arterial coronaria
    Disease: Version SOC Term Classification Code Term Level
    9 10011076 Coronary artery atherosclerosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) IT (Completed) FR (Completed) DE (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2019-001076-11 Sponsor Protocol Number: CTQJ230A12301 Start Date*: 2019-12-19
    Sponsor Name:Novartis Pharma AG
    Full Title: A randomized double-blind, placebo-controlled, multicenter trial assessing the impact of lipoprotein (a) lowering with pelacarsen (TQJ230) on major cardiovascular events in patients with establishe...
    Medical condition: Cardiovascular Disease
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004866 10051614 Arteriosclerotic cardiovascular disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) AT (Trial now transitioned) GB (GB - no longer in EU/EEA) DK (Trial now transitioned) SK (Trial now transitioned) FR (Trial now transitioned) IT (Trial now transitioned) GR (Trial now transitioned) PT (Trial now transitioned) SE (Trial now transitioned) NL (Ongoing) BG (Trial now transitioned) BE (Trial now transitioned) NO (Trial now transitioned) SI (Trial now transitioned) RO (Trial now transitioned) IS (Trial now transitioned)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 10 00:21:24 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA